Biological
IgPro10
IgPro10 is a biological therapy with 5 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
5
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 3 completed trials
Completion Rate
100%(3/3)
Active Trials
1(20%)
Results Posted
100%(3 trials)
Phase Distribution
Ph phase_3
1
20%
Ph phase_4
2
40%
Ph phase_2
2
40%
Phase Distribution
0
Early Stage
2
Mid Stage
3
Late Stage
Phase Distribution5 total trials
Phase 2Efficacy & side effects
2(40.0%)
Phase 3Large-scale testing
1(20.0%)
Phase 4Post-market surveillance
2(40.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
75.0%
3 of 4 finished
Non-Completion Rate
25.0%
1 ended early
Currently Active
1
trials recruiting
Total Trials
5
all time
Status Distribution
Active(1)
Completed(3)
Terminated(1)
Detailed Status
Completed3
Recruiting1
Withdrawn1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
1
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 22 (40.0%)
Phase 31 (20.0%)
Phase 42 (40.0%)
Trials by Status
completed360%
recruiting120%
withdrawn120%
Recent Activity
1 active trials
Showing 5 of 5
recruitingphase_4
Two Dose Levels of Privigen in Pediatric CIDP
NCT03684018
completedphase_2
Safety and Pharmacokinetics of IgPro20 and IgPro10 in Adults With Systemic Sclerosis (SSc)
NCT04137224
withdrawnphase_2
Efficacy and Safety of IgPro10 in Adults With Systemic Sclerosis (SSc)
NCT04138485
completedphase_3
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)
NCT01545076
completedphase_4
A Safety Study of Intravenous Immunoglobulin in Patients With Chronic Immune Thrombocytopenic Purpura (ITP)
NCT01390649
Clinical Trials (5)
Showing 5 of 5 trials
NCT03684018Phase 4
Two Dose Levels of Privigen in Pediatric CIDP
NCT04137224Phase 2
Safety and Pharmacokinetics of IgPro20 and IgPro10 in Adults With Systemic Sclerosis (SSc)
NCT04138485Phase 2
Efficacy and Safety of IgPro10 in Adults With Systemic Sclerosis (SSc)
NCT01545076Phase 3
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)
NCT01390649Phase 4
A Safety Study of Intravenous Immunoglobulin in Patients With Chronic Immune Thrombocytopenic Purpura (ITP)
All 5 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 5